COMP <GO>
XENE vs UNH // ALTMAN Z-SCORE & DEBT/EQUITY
Xenon Pharmaceuticals Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: XENE 3
— UNH 11
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: XENE
LAST: $37.41 (-0.35%) • MKT CAP: $3.64B
balance-sheet
26.00
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
balance-sheet
3.12
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (XENE VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | XENE | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 88.57% | -47.57 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 11.47% | -46.47 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 16.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -7.70% | 6.48% | -14.18 | UNH | /fcf-yield <GO> |
| Operating Margin | -36.70% | 4.82% | -41.52 | UNH | /operating-margins <GO> |
| Net Profit Margin | -34.00% | 3.14% | -37.14 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | 7.70% | 6.46% | +1.24 | XENE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 26.00 | 3.12 | +22.88 | XENE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 6.74% | +0.46 | UNH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.3 | 56.0 | -11.77 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 0.33 | +0.77 | XENE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 29.0x | 17.1x | +11.91 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.64B | $364.66B | -$361.02B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | XENE REV | UNH REV | XENE GROSS % | UNH GROSS % | XENE FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $447.57B | — | 88.7% | -$279.9M | $16.07B |
| FY 2024 | $0 | $400.28B | — | 88.3% | -$184.5M | $20.70B |
| FY 2023 | $0 | $371.62B | — | 89.6% | -$151.1M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
XENE // BETA 1.10
UNH // BETA 0.33